Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699751 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
A Phase 3 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 921
- Enrollment target
NCT00699751 is a Phase 3 study that has completed, run by Bayer. The registered enrollment target is 921 participants.
The verdict
NCT00699751, a Phase 3 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 921 participants
- Enrollment target
Study Summary
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
Interventions
- DRUG Placebo
- DRUG Radium-223 dichloride (Xofigo, BAY88-8223)
- DRUG Best standard of care (BSoC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 921 participants |
| Start Date | 2008-06-12 |
| Est. Completion | 2014-02-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00699751
The ClinicalTrials.gov registry entry for NCT00699751 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 921 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00699751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00699751 about?
NCT00699751 is a clinical study titled "A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases". ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
What is the current status of trial NCT00699751?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 921 participants. The study started on 2008-06-12. Estimated completion is 2014-02-13.
What interventions are being tested in trial NCT00699751?
The interventions under investigation include: Placebo (DRUG), Radium-223 dichloride (Xofigo, BAY88-8223) (DRUG), Best standard of care (BSoC) (DRUG).
Who is sponsoring clinical trial NCT00699751?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.